Medtronic starts brain stent trial:
This article was originally published in Clinica
The first US patient has been treated with Medtronic's INX neurovascular stent in a feasibility study on atherosclerotic disease. The study, at the State University of New York in Buffalo, follows an earlier feasibility study on intracranial wide-necked aneurysms. The INX stent has been specially designed for use in the highly tortuous vessels at the skull base and will be tested in a broad range of sizes.
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.